Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Empiric withdraws statements over potential Unite cost synergies

(Sharecast News) - Empiric Student Property issued a clarification on Monday, after what i called "unauthorised comments" regarding potential synergies and regulatory risks linked to a possible takeover by the Unite Group were made during a meeting with investors and an analyst on 5 June. The company confirmed that the meeting took place shortly after it announced it had entered an initial due diligence period with Unite, placing it within an offer period under the Takeover Code.

However, the meeting was held without the presence of a financial adviser or corporate broker, breaching rule 20.2(b) of the code.

Following the meeting, the analyst published statements suggesting that significant cost synergies could be achieved and that the CMA might review Empiric's presence in six cities, potentially requiring asset disposals.

Empiric said it had now fully retracted those statements, advising shareholders to disregard them.

The company acknowledged that the synergy estimates were not compiled with the care required under rule 28.1(a), and that there had been no engagement with the Competition and Markets Authority to date.

At 1252 BST, shares in Empiric Student Property were flat at 103.2p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.